Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 19, 2026

Korro Bio, Inc. (KRRO)

A forensic read on Korro Bio, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Distress

Financial health

-13.3

Distress distance

Clean

Earnings quality

Forensic signals

-228.0%

ROE

181.5%

Revenue growth

The financial-health reading above compares this company's equity at BOOK value, not at what the market currently pays for it — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Korro Bio, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -13.3, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 2 forensic signals were flagged in its latest SEC filings, led by share count (stock split).

What the filings flag

n/m (stock split)

FY2022–FY2025

Share count (stock split). Diluted share count changed +3582% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +232.7%/yr figure isn't a real buyback/dilution read here.

120% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 120% of revenue in FY2025 — about $0.81 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 5.3% a year, above the level at which the count is a material claim on a stake, and only one year's change is on file — enough to state what a holder gave up, not enough to say whether the rate is climbing or coming down. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.

Key fundamentals

Latest Revenue$6.4M

Revenue Growth YoY+181.5%

Net Margin-1834.5%

Free Cash Flow-$79.1M

Return on Equity-228.0%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Korro Bio, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Sep 19, 2026. Forensic signals flag probability, not certainty.